nach oben

Clinical Rheumatology

Erschienen in:

01.04.2020 | Case Based Review

A patient with primary Sjogren’s syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review

verfasst von: Leanna M. Wise, Daniel G. Arkfeld

Erschienen in: Clinical Rheumatology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Primary Sjogren’s syndrome (pSS) can have a myriad of presentations, ranging from mild xerostomia to more diffuse systemic involvement. It is well established that pSS is associated with a variety of pulmonary pathologies, and it is also known that pSS patients are at higher risk for lymphoma development. Here, we present an unusual case of a woman with primary Sjogren’s syndrome who had both diffuse cystic lung disease as well as extranodal MALT lymphoma, successfully treated for both conditions with the CD-20 monoclonal antibody rituximab.

Fox RI (2005) Sjögren’s syndrome. Lancet 366(9482):321–331. https://doi.org/10.1016/S0140-6736(05)66990-5 CrossRefPubMed

Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, Calvo-Alen J, Jiménez-Alonso J, Micó ML, Beltrán J, Belenguer R, Pallarés L, GEMESS Study Group (2008) Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87(4):210–219. https://doi.org/10.1097/MD.0b013e318181e6af CrossRef

Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA (2006) Epidemiology of primary Sjogren’s syndrome in north-west Greece, 1982-2003. Rheumatology (Oxford) 45(2):187–191. https://doi.org/10.1093/rheumatology/kei107 CrossRef

Kvarnstrom M, Ottosson V, Nordmark B, Wahren-Herlenius M (2015) Incident cases of primary Sjogren’s syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol 44(2):135–142. https://doi.org/10.3109/03009742.2014.931457 CrossRefPubMed

Maciel G, Crowson CS, Matteson EL, Cornec D (2017) Prevalence of primary Sjogren’s syndrome in a US population-based cohort. Arthritis Care Res (Hoboken) 69(10):1612–1616. https://doi.org/10.1002/acr.23173 CrossRef

Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R (2015) Epidemiology of primary Sjogren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74(11):1983–1989. https://doi.org/10.1136/annrheumdis-2014-205375 CrossRefPubMed

Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH (2006) Interstitial lung disease in primary Sjogren syndrome. Chest 130(5):1489–1495. https://doi.org/10.1378/chest.130.5.1489 CrossRefPubMed

Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Lévesque H, Marie I (2017) Interstitial lung disease in primary Sjogren’s syndrome. Autoimmun Rev 16(1):48–54. https://doi.org/10.1016/j.autrev.2016.09.017 CrossRefPubMed

Ito I, Nagai S, Kitaichi M et al (2005) Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 171(6):632–638. https://doi.org/10.1164/rccm.200403-417OC CrossRefPubMed

10.

Jagirdar J, Chikkamuniyappa S, Sirohi D, McCarthy MJ, Peters JI (2013) Cystic lung lesions in Sjogren syndrome: analysis of lymphocyte subsets in tissue with clinico-radiologic-pathologic correlation. Ann Diagn Pathol 17(1):113–116. https://doi.org/10.1016/j.anndiagpath.2012.03.005 CrossRefPubMed

11.

Martínez-Balzano CD, Touray S, Kopec S (2016) Cystic lung disease among patients with Sjögren syndrome: frequency, natural history, and associated risk factors. Chest 150(3):631–639. https://doi.org/10.1016/j.chest.2016.05.015 CrossRefPubMed

12.

Panchabhai TS, Farver C, Highland KB (2016) Lymphocytic interstitial pneumonia. Clin Chest Med 37(3):463–474. https://doi.org/10.1016/j.ccm.2016.04.009 CrossRefPubMed

13.

Xu KF, Feng R, Cui H et al (2016) Diffuse cystic lung diseases: diagnostic considerations. Semin Respir Crit Care Med 37(3):457–467. https://doi.org/10.1055/s-0036-1580690 CrossRefPubMed

14.

Papageorgiou A, Voulgarelis M, Tzioufas AG (2015) Clinical picture, outcome and predictive factors of lymphoma in Sjgren syndrome. Autoimmun Rev 14(7):641–649. https://doi.org/10.1016/j.autrev.2015.03.004 CrossRefPubMed

15.

Alunno A, Leone MC, Giacomelli R, Gerli R, Carubbi F (2018) Lymphoma and lymphomagenesis in primary Sjogren’s syndrome. Front Med (Lausanne) 5:102. https://doi.org/10.3389/fmed.2018.00102 CrossRef

16.

Fragkioudaki S, Mavragani CP, Moutsopoulos HM (2016) Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine (Baltimore) 95(25):e3766. https://doi.org/10.1097/md.0000000000003766 CrossRef

17.

Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum 46(3):741–747. https://doi.org/10.1002/art.10221 CrossRefPubMed

18.

Defrancesco I, Arcaini L (2018) Overview on the management of non-gastric MALT lymphomas. Best Pract Res Clin Haematol 31(1):57–64. https://doi.org/10.1016/j.beha.2017.11.001 CrossRefPubMed

19.

Fox RI, Maruyama T (1997) Pathogenesis and treatment of Sjogren’s syndrome. Curr Opin Rheumatol 9(5):393–399CrossRef

20.

Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X (2006) Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren’s syndrome. Proc Natl Acad Sci U S A 103(8):2770–2775. https://doi.org/10.1073/pnas.0510837103 CrossRefPubMedPubMedCentral

21.

Li Y, Zhang K, Chen H et al (2013) A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjogren’s syndrome at 7q11.23. Nat Genet 45(11):1361–1365. https://doi.org/10.1038/ng.2779 CrossRefPubMed

22.

Mingueneau M, Boudaoud S, Haskett S et al (2016) Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren’s signature correlating with disease activity and glandular inflammation. J allergy Clin Immunol 137 (6):1809-1821.e1812. doi:https://doi.org/10.1016/j.jaci.2016.01.024

23.

Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sjogren’s syndrome. Nat Rev Rheumatol 9(9):544–556. https://doi.org/10.1038/nrrheum.2013.110 CrossRefPubMed

24.

Tasaki S, Suzuki K, Nishikawa A, Kassai Y, Takiguchi M, Kurisu R, Okuzono Y, Miyazaki T, Takeshita M, Yoshimoto K, Yasuoka H, Yamaoka K, Ikeura K, Tsunoda K, Morita R, Yoshimura A, Toyoshiba H, Takeuchi T (2017) Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjogren’s syndrome. Ann Rheum Dis 76(8):1458–1466. https://doi.org/10.1136/annrheumdis-2016-210788 CrossRefPubMedPubMedCentral

25.

Deshmukh US, Nandula SR, Thimmalapura PR, Scindia YM, Bagavant H (2009) Activation of innate immune responses through toll-like receptor 3 causes a rapid loss of salivary gland function. J Oral Pathol Med 38(1):42–47. https://doi.org/10.1111/j.1600-0714.2008.00700.x CrossRefPubMedPubMedCentral

26.

Jacob N, Guo S, Mathian A, Koss MN, Gindea S, Putterman C, Jacob CO, Stohl W (2011) B cell and BAFF dependence of IFN-alpha-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol 186(8):4984–4993. https://doi.org/10.4049/jimmunol.1000466 CrossRefPubMedPubMedCentral

27.

Daridon C, Devauchelle V, Hutin P, le Berre R, Martins-Carvalho C, Bendaoud B, Dueymes M, Saraux A, Youinou P, Pers JO (2007) Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheum 56(4):1134–1144. https://doi.org/10.1002/art.22458 CrossRefPubMed

28.

Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190(11):1697–1710. https://doi.org/10.1084/jem.190.11.1697 CrossRefPubMedPubMedCentral

29.

Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome. Ann Rheum Dis 62(2):168–171. https://doi.org/10.1136/ard.62.2.168 CrossRefPubMedPubMedCentral

30.

Halse A, Tengner P, Wahren-Herlenius M, Haga H, Jonsson R (1999) Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjogren’s syndrome. Scand J Immunol 49(5):533–538. https://doi.org/10.1046/j.1365-3083.1999.00533.x CrossRefPubMed

31.

Perrier S, Serre AF, Dubost JJ, Beaujon G, Plazonnet MP, Albuisson E, Sauvezie B (2000) Increased serum levels of interleukin 10 in Sjogren’s syndrome; correlation with increased IgG1. J Rheumatol 27(4):935–939PubMed

32.

Shen L, Suresh L, Li H, Zhang C, Kumar V, Pankewycz O, Ambrus JL Jr (2009) IL-14 alpha, the nexus for primary Sjogren’s disease in mice and humans. Clin Immunol 130(3):304–312. https://doi.org/10.1016/j.clim.2008.10.006 CrossRefPubMed

33.

Uffmann M, Kiener HP, Bankier AA et al (2001) Lung manifestation in asymptomatic patients with primary Sjogren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging 16(4):282–289CrossRef

34.

Lohrmann C, Uhl M, Warnatz K, Ghanem N, Kotter E, Schaefer O, Langer M (2004) High-resolution CT imaging of the lung for patients with primary Sjogren’s syndrome. Eur J Radiol 52(2):137–143. https://doi.org/10.1016/j.ejrad.2004.01.006 CrossRefPubMed

35.

Watanabe M, Naniwa T, Hara M, Arakawa T, Maeda T (2010) Pulmonary manifestations in Sjogren’s syndrome: correlation analysis between chest computed tomographic findings and clinical subsets with poor prognosis in 80 patients. J Rheumatol 37(2):365–373. https://doi.org/10.3899/jrheum.090507 CrossRefPubMed

36.

Koyama M, Johkoh T, Honda O, Mihara N, Kozuka T, Tomiyama N, Hamada S, Nakamura H (2001) Pulmonary involvement in primary Sjogren’s syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. J Thorac Imaging 16(4):290–296CrossRef

37.

Matsuyama N, Ashizawa K, Okimoto T, Kadota J, Amano H, Hayashi K (2003) Pulmonary lesions associated with Sjogren’s syndrome: radiographic and CT findings. Br J Radiol 76(912):880–884. https://doi.org/10.1259/bjr/18937619 CrossRefPubMed

38.

Franquet T, Gimenez A, Monill JM, Diaz C, Geli C (1997) Primary Sjogren’s syndrome and associated lung disease: CT findings in 50 patients. AJR Am J Roentgenol 169(3):655–658. https://doi.org/10.2214/ajr.169.3.9275871 CrossRefPubMed

39.

Lechtman S, Debray MP, Crestani B, Bancal C, Hourseau M, Dossier A, Alexandra JF, Chauveheid MP, Papo T, Sacre K (2017) Cystic lung disease in Sjögren’s syndrome: an observational study. Joint Bone Spine 84(3):317–321. https://doi.org/10.1016/j.jbspin.2016.05.019 CrossRefPubMed

40.

Rajagopala S, Singh N, Gupta K, Gupta D (2010) Pulmonary amyloidosis in Sjogren’s syndrome: a case report and systematic review of the literature. Respirology 15(5):860–866. https://doi.org/10.1111/j.1440-1843.2010.01772.x CrossRefPubMed

41.

Shi JH, Liu HR, Xu WB et al (2009) Pulmonary manifestations of Sjogren’s syndrome. Respiration 78(4):377–386. https://doi.org/10.1159/000214841 CrossRefPubMed

42.

Lynch DA (2009) Lung disease related to collagen vascular disease. J Thorac Imaging 24(4):299–309. https://doi.org/10.1097/RTI.0b013e3181c1acec CrossRefPubMed

43.

Chen MH, Chen CK, Chou HP, Tsai CY, Chang DM (2016) Rituximab therapy in primary Sjogren’s syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol 34(6):1077–1084

44.

Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S (2016) Pulmonary manifestations of Sjogren’s syndrome. Eur Respir Rev 25(140):110–123. https://doi.org/10.1183/16000617.0011-2016 CrossRefPubMed

45.

Nocturne G, Mariette X (2015) Sjögren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 168(3):317–327. https://doi.org/10.1111/bjh.13192 CrossRefPubMed

46.

Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344. https://doi.org/10.1001/archinte.165.20.2337 CrossRefPubMed

47.

Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88(5):284–293. https://doi.org/10.1097/MD.0b013e3181b76ab5 CrossRef

48.

Nocturne G, Virone A, Ng WF et al (2016) Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol 68(4):977–985. https://doi.org/10.1002/art.39518 CrossRefPubMed

49.

Kluka EM, Bauer PR, Aubry MC, Ryu JH (2013) Enlarging lung nodules and cysts in a 53-year-old woman with primary Sjogren syndrome. Chest 143(1):258–261. https://doi.org/10.1378/chest.12-0547 CrossRefPubMed

50.

Kocijancic K, Kocijancic I (2006) Primary Sjogren’s syndrome associated with non-Hodgkin’s lymphoma of salivary gland and cystic lung disease. Coll Antropol 30(4):925–927PubMed

Titel: A patient with primary Sjogren’s syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review
verfasst von: Leanna M. Wise
Daniel G. Arkfeld
Publikationsdatum: 01.04.2020
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 4/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04886-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Correction to: The association between anxiety and disease activity and quality of life in rheumatoid arthritis: a systematic review and meta-analysis

Experience of musculoskeletal ultrasound scanning improves physicians’ physical examination skills in assessment of synovitis

Ultrasound salivary gland involvement in Sjogren’s syndrome vs. other connective tissue diseases: is it autoantibody and gland dependent?

Pain catastrophizing affects stair climbing ability in individuals with knee osteoarthritis

Disease activity–based management of rheumatoid arthritis in Dutch daily clinical practice has improved over the past decade